Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RNAC - Cartesian Therapeutics, Inc.

IEX Last Trade
19.22
-0.540   -2.810%

Share volume: 200
Last Updated: Fri 27 Dec 2024 05:26:10 PM CET
Research and Development in Biotechnology (except Nanobiotechnology): -0.39%

PREVIOUS CLOSE
CHG
CHG%
$19.76
-0.54
-2.73%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
35%
Profitability 50%
Dept financing 25%
Liquidity 60%
Performance 16%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-4.55%
1 Month
-0.97%
3 Months
6.39%
6 Months
-25.37%
1 Year
-17.53%
2 Year
1,626.17%
Key data
Stock price
$19.22
P/E Ratio 
-1.28
DAY RANGE
$19.54 - $19.76
EPS 
-$32.91
52 WEEK RANGE
$0.75 - $41.21
52 WEEK CHANGE
-$16.80
MARKET CAP 
298.499 M
YIELD 
N/A
SHARES OUTSTANDING 
21.382 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/11/2024
BETA 
0.00
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$216,341
AVERAGE 30 VOLUME 
$158,253
Company detail
CEO: Carsten Brunn
Region: US
Website: www.cartesiantherapeutics.com
Employees: 64
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Cartesian Therapeutics, Inc., formerly Selecta Biosciences, Inc., is a clinical-stage company, which is engaged in ribonucleic acid (RNA) cell therapies for the treatment of autoimmune diseases.

Recent news